{"id":"nct:NCT05929066","kind":"trial","title":"A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight","authors":["Eli Lilly and Company"],"author_count":1,"year":2023,"published":"2023-07-03","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT05929066","source_url":"https://clinicaltrials.gov/study/NCT05929066","archive_url":"https://space-kitty.com/papers/nct:NCT05929066","updated":"2026-08-21","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additional 24 weeks.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Obesity","Overweight","Osteoarthritis, Knee","Obstructive Sleep Apnea"],"details":{"acronym":"TRIUMPH-1","status":"COMPLETED","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":2335,"sponsor":"Eli Lilly and Company","conditions":["Obesity","Overweight","Osteoarthritis, Knee","Obstructive Sleep Apnea"],"interventions":["DRUG: Retatrutide","DRUG: Placebo"],"start_date":"2023-07-10","start_date_type":"ACTUAL","primary_completion_date":"2026-04-06","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"glp1-metabolic","name":"GLP-1 & Incretin Therapies","domain_slug":"medicine"}],"cited_in_dossiers":[]}